Fig. 1From: Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancerFormulation and characterization of Alpelisib-loaded nanoparticles. a Schematic illustration of the formulation of NP and ACNP loaded with Alpelisib. PVA: polyvinylalcohol; EDC: 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride; NHS: N-Hydroxysuccinimide. b SEM and c TEM images of NP-Alpelisib and ACNP-Alpelisib. Scale bars: 1 µm b, 0.2 µm cBack to article page